Announcement

Collapse
No announcement yet.

Cancer

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • #16
    Recently Published Study Shows Effective Treatment for Early-Stage Breast Cancer

    The TARGIT Collaborative Group (TCG) is pleased to announce publication of the long-term results of the Targeted Intraoperative Radiotherapy Trial (TARGIT-A Trial) comparing partial breast single fraction targeted intraoperative radiotherapy (TARGIT-IORT) to 3-6 week post-operative whole breast radiotherapy, demonstrating equivalent long-term outcomes between the two treatments. The results of the trial were published on August 19, 2020 in the British Medical Journal (www.bmj.com/content/370/bmj.m2836).

    The TARGIT-A Trial was a 2,298-patient multicenter, international, randomized controlled trial evaluating the use of TARGIT-IORT using the Intrabeam System (Carl Zeiss Meditec, Inc.) as a method of delivering IORT. TARGIT-IORT is typically administered in less than 30 minutes at the time of lumpectomy. TARGIT-IORT is the only method of delivering IORT widely available in the U.S. for which effectiveness has been proven in a randomized control trial.

    Dr. Valery Uhl, Radiation Oncologist and President of the TCG, stated: “We now have long-term proof that TARGIT-IORT is not only an effective—but in many ways superior—treatment for early-stage breast cancer. Every hospital where breast cancer surgery is performed should offer this form of radiation treatment to their breast cancer patients. Not only are long-term local control and cancer survival outcomes similar to whole breast radiotherapy, but mortality from other causes was lower in the IORT arm. TARGIT-IORT should be considered the new standard of treatment for early-stage breast cancer based on this large, multi-institutional, prospective, randomized controlled trial.”

    The TARGIT-A trial is largely responsible for the widespread adoption of IORT as a treatment option for early-stage breast cancer in the U.S. IORT is now covered by Medicare and most health plans. According to Breast Surgeon, Dr. Dennis Holmes, a TCG Founder and TARGIT-A Trial publication co-author, “in addition to being efficacious, separate publications have shown TARGIT-IORT to be associated with fewer side effects, improved quality of life, and reduced healthcare cost compared to whole breast radiotherapy.”

    Dr. Barry Rosen, Breast Surgeon and Secretary/Treasurer of TCG noted: “TARGIT-IORT is a safe, convenient, cost-effective alternative to WBRT that has virtually no side-effects and better cosmetic outcomes by virtue of its targeted therapy. I believe this establishes a new standard for patient-centered, precision oncology and should be offered to all breast cancer patients that meet eligibility requirements. Furthermore, the lower non-cancer mortality rates associated with IORT warrants further study.”: https://www.businesswire.com/news/ho...y-Stage-Breast

    Keep your friends close and your enemies closer

    Comment


    • #17
      Study finds two drugs can reduce cancer spread after tumor removal

      A research group from Tel Aviv University (TAU) successfully reduced metastatic spread following tumor removal surgery in colorectal cancer patients.

      Using a short treatment around the time of the surgery, they were able to reduce stress responses and physiological inflammation, thus preventing the development of metastases in the years following the surgery.

      The study, recently published in the American Cancer Society journal Cancer, was led by Prof. Shamgar Ben-Eliyahu from the TAU School of Psychological Sciences and Sagol School of Neuroscience, and Dr. Oded Zmora from Shamir (Assaf Harofeh) Medical Center.

      The three-year study involved 34 patients. Over the course of 20 days — from five days prior to surgery until two weeks afterward — 16 of the patients received anti-anxiety and blood pressure-reducing drug Propranolol (Deralin) and anti-inflammatory analgesic Etodolac (Etopan), and 18 received a placebo treatment as a control group.

      Only two out of 16 patients receiving the drug treatment exhibited metastatic disease. In the control group, six out of 18 developed metastases, which is the usual rate for colorectal cancer patients.

      The treatment led to a reduction in the metastatic potential of the tumor and potentially the residual cancer cells.

      In addition, the drugs triggered good changes in patients’ white blood cell number and type, indicating a reduced chance of disease recurrence.

      “When the body is in a state of stress, whether physiological (from surgery) or psychological, this causes a release of high amounts of two types of hormones, prostaglandins and catecholamines,” Ben-Eliyahu explained.

      “These hormones suppress the activity of the immune cells, thus indirectly promoting the development of cancer metastases. In addition, these hormones also directly promote the acquisition of metastatic traits in cancer tissue.,” he continued.

      “Our study shows that inexpensive, accessible medication treatment could be used to reduce body stress responses and inflammation associated with surgery, which significantly reduces the risk of metastases that might be detected months or years after surgery.”

      Ben-Eliyahu now plans a large-scale clinical study to further test this treatment.: https://www.israel21c.org/study-find...tumor-removal/ - https://acsjournals.onlinelibrary.wi...002/cncr.32950

      Keep your friends close and your enemies closer

      Comment

      antalya escort
      antalya escort
      Working...
      X